Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ergoloid mesylates + 5-hydroxytryptophan
- Development stage
- Phase 2
- Lead developer
- Purposeful
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of ergoloid mesylates and 5-hydroxytryptophan (5-HTP) currently under investigation for the treatment of Fragile X syndrome. Ergoloid mesylates is a mixture of dihydrogenated ergot alkaloids (dihydroergocornine, dihydroergocristine, and dihydroergocryptine) that acts as a multi-receptor modulator with activity at dopaminergic, serotonergic, and adrenergic receptors. 5-HTP is a naturally occurring amino acid and metabolic precursor to the neurotransmitter serotonin. This specific combination was identified using artificial intelligence by the biotech company Purposeful and is being evaluated in a Phase 2 clinical trial led by Dr. Elizabeth Berry-Kravis at Rush University Medical Center. Preclinical studies in mouse models of Fragile X syndrome suggested that the combination could reverse behavioral and cognitive symptoms by synergistically modulating central neurotransmission.
- Other names
- ergoloid mesylates + 5-hydroxytryptophanEM + 5-HTP combination
02
Targets
ADRA2A (α2A)ADRB1 (β1)DRD (Dopamine receptors)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))ADRA1A (α1A)
Beyond the preview
Go deeper on ergoloid mesylates + 5-hydroxytryptophan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ergoloid mesylates + 5-hydroxytryptophan.